Pricing & Access· August 18, 2026 · 16 min read
DTX401's August 23 PDUFA: Payers Face a Cornstarch-Replacement Gene Therapy
By Ran Chen#Gene Therapy#Rare Disease#Medicaid
Topic
Medicaid
State Medicaid coverage, preferred drug lists, prior authorization, supplemental rebates, and access variation.
Pricing & Access· August 17, 2026 · 25 min read
Medicaid's September 10 Deadline: The Coverage Trade for GENEROUS Pricing
By Ran Chen#Medicaid#Drug Pricing#Payer Policy
Pricing & Access· August 16, 2026 · 18 min read
Hepatitis C Treatment Access in 2026: Generic Economics, PA, and Sobriety
Approvals· July 27, 2026 · 18 min read
Sickle Cell Disease Treatment Access Landscape: Casgevy, Lyfgenia & Oxbryta
Pricing & Access· June 28, 2026 · 21 min read
Casgevy Access Guide: CMS CGT Model, State Medicaid Criteria, and the ATC Network
By Ran Chen#Medicaid#Prior Authorization#Gene Therapy
Policy· June 28, 2026 · 17 min read
Medicaid Drug Rebate Program Explained: AMP, Best Price, and the CPI Penalty
By Ran Chen#Medicaid#Drug Pricing#Payer Policy
Generics· June 22, 2026 · 19 min read
Generic Vyvanse (Lisdexamfetamine): Shortage Status, API Quotas, and NADAC Price Erosion
By Ran Chen#Generics#Drug Pricing#Supply Chain
Pricing & Access· June 12, 2026 · 9 min read
CMS NADAC by the numbers: 696K records, median $0.19/unit, brands 81× generic
By Ran Chen#Drug Pricing#Medicaid#Formulary Strategy
Pricing & Access· June 6, 2026 · 10 min read
MassHealth GLP-1 coverage: PA criteria and what stays covered after July 2026
By Ran Chen#GLP-1#Medicaid#Prior Authorization
Pricing & Access· June 6, 2026 · 12 min read
Medi-Cal GLP-1 coverage: what changed January 2026, what stays covered, and PA pathways
By Ran Chen#GLP-1#Medicaid#Prior Authorization